Trial Information
Inclusion Criteria:
- child
- non metastatic rhabdomyosarcoma
- adequate heart, kidney, liver function
Exclusion Criteria:
- age over 21 years, under 6 months
- metastatic disease
- heart, kidney, liver disease
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label
Outcome Measure:
event free survival
Principal Investigator
Iris Kventsel, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Sheba Medical Center
Authority:
Israel: Israeli Health Ministry Pharmaceutical Administration
Study ID:
SHEBA-06-4013-IK-CTIL
NCT ID:
NCT00339118
Start Date:
Completion Date:
Related Keywords:
- Rhabdomyosarcoma
- Rhabdomyosarcoma
- Sarcoma